Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) shot up 5.7% on Wednesday . The company traded as high as $20.16 and last traded at $20.16. 7,396 shares traded hands during trading, a decline of 95% from the average session volume of 152,312 shares. The stock had previously closed at $19.07.
The business's fifty day moving average is $23.12.
A number of large investors have recently bought and sold shares of RAPP. TD Asset Management Inc bought a new stake in shares of Rapport Therapeutics in the 2nd quarter worth about $2,361,000. Johnson & Johnson acquired a new stake in shares of Rapport Therapeutics during the second quarter worth approximately $58,105,000. Sofinnova Investments Inc. bought a new stake in shares of Rapport Therapeutics during the second quarter worth $45,393,000. Davidson Kempner Capital Management LP acquired a new stake in shares of Rapport Therapeutics in the second quarter valued at $229,000. Finally, ARCH Venture Management LLC acquired a new position in Rapport Therapeutics during the 2nd quarter worth about $86,730,000.
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.